Sphingosine 1-phosphate Receptor Modulator

This page covers all Sphingosine 1-phosphate Receptor Modulator drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5, S1P1 receptor (sphingosine-1-phosphate receptor 1).

Targets

Sphingosine 1-phosphate receptor 1 · Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5 · S1P1 receptor (sphingosine-1-phosphate receptor 1) · S1P1, S1P3, S1P4, S1P5 (sphingosine-1-phosphate receptors) · S1P1

Marketed (5)

• Zeposia · Bristol-Myers Squibb · Immunology · 800
  Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression.
• Velsipity · Pfizer Inc. · Immunology
  Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs.
• Etrasimod · Pfizer · Immunology
  Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes.
• Gilenya · Novartis · Immunology
  Gilenya works by binding to and blocking the S1P1 receptor, preventing immune cells from leaving the lymph nodes and reducing inflammation in the central nervous system.
• fingolimob (FTY) · University Hospital, Clermont-Ferrand · Immunology
  Fingolimob is a sphingosine-1-phosphate (S1P) receptor modulator that sequesters lymphocytes in lymphoid tissues, reducing their migration to inflamed sites.

Phase 3 pipeline (1)

• Placebo matching fingolimod · Biogen · Immunology
  Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing their infiltration into the central nervous system.

Phase 2 pipeline (1)

• Apilimod Dimesylate Capsule · OrphAI Therapeutics · Immunology
  Apilimod Dimesylate Capsule is a sphingosine 1-phosphate receptor modulator.